BusinessNews.ph

Blog

  • COSMOPlat Introduces Full-Stack AI to Hong Kong for Trillion-Dollar Industrial Digitalization

    Currently, digital transformation has become the core proposition of global industrial upgrading, and the manufacturing industry is also undergoing a disruptive transformation from being “experience-driven” to “data intelligence-driven”. In this process, the deep integration of artificial intelligence and industrial scenarios has become the key to resolving manufacturing complexity and unleashing productivity.  The introduction of the Action Plan for Integrating and Empowering Industrial Internet and Artificial Intelligence by MIIT further marks the upgrade of “AI + Manufacturing” from an optional pathway to a mandatory one, giving rise to a blue ocean of value worth tens of trillions.

    As a deep participant and leader in the digital and intelligent transformation of the manufacturing industry, COSMOPlat IoT Technology Co., Ltd. (“COSMOPlat”) has, based on its profound understanding of massive data and complex scenarios in the industrial field, built a full-stack AI technology system that includes training and inference platform, large models, intelligent agent development and application platforms. This has not only redefined the implementation path of industrial digitalization and intelligentization, but also continuously strengthened its technical barriers in industrial practice, building a solid and difficult-to-replicate moat, and is expected to benefit deeply from the dividends of industrial digital and intelligent transformation and development. On January 30, COSMOPlat submitted a listing application to the HKEX, embarking on a new chapter of value realization.

    AI Restructuring Industrial Digitalization: Full-stack Architecture and Flywheel Effect Build Core Barriers
    In traditional perception, the industrial internet is a platform for data connection and circulation, and its technical boundaries remain more at the levels of equipment access, data collection, and process visualization. However, through its original “space-air-ground integrated” full-stack AI technology system, COSMOPlat has deeply embedded “AI+” into its technology architecture, achieving an intelligent closed-loop across the entire chain from perception and decision-making to execution, transforming data into intelligent decision-making capabilities, completely overturning the technology logic of the traditional industrial internet, and building an inimitable technology moat.

    At the “space” level, COSMOPlat utilizes “COSMOMind”, the first domestic vertical large model based on an industrial internet platform, as its decision-making hub. “COSMOMind” deeply integrates Haier Group’s over 40 years of manufacturing knowledge, as well as expert models and high-quality multimodal datasets accumulated on the COSMOMind Industrial Big Data. It possesses significant advantages in industrial scenario analysis, knowledge Q&A, and logical reasoning, with a retrieval accuracy rate of up to 93% in industrial knowledge fusion and retrieval. Through the “one industry, one model” strategy, COSMOPlat has developed industry-specific large models for enterprises in home appliances, energy and chemicals, energy and carbon industries, providing intelligent decision-making support for major industrial scenarios including research and development design, production manufacturing, operation services and dual-carbon management.

    Industry intelligent agents and industrial software serve as the “air link”, transforming the decision-making instructions of large models into more flexible human-machine interaction methods and more efficient execution capabilities. As of the Latest Practicable Date, COSMOPlat has developed 57 industrial intelligent agents covering over 40 core scenarios across 3 major industries, which can handle key industrial functions such as process optimization, equipment management, and smart energy and carbon, helping customers achieve intelligent control of industrial processes, shorten process parameter adjustment cycles, improve equipment operation and maintenance efficiency, and reduce production energy consumption and energy costs.

    At the “ground” level, intelligent terminals and automation equipment, acting as the executing limbs, transform AI capabilities into actual production actions and integrate them into the entire manufacturing process, achieving efficient synergy among data, equipment and scenarios, driving industrial AI from isolated intelligent applications to domain-wide intelligence, creating value-added throughout the entire process for customers across various industries, and maximizing the release of data value.

    Relying on the “space-air-ground integrated” full-stack AI technology system, COSMOPlat has achieved full-link intelligence across “perception-analysis-decision-execution-feedback”, forming a unique flywheel effect of “data accumulation—model refinement—intelligent agent deployment—data reinforcement”, achieving self-reinforcement and a virtuous cycle where “more data is generated through use, models become more precise through use, and intelligent agent scenarios become broader through use”, enabling COSMOPlat’s AI capabilities to continuously evolve in practice and building a solid technology barrier.

    Practical Evidence: AI Empowerment from Concept to Significant Scenario Implementation Results
    The value of technology must ultimately be tested by the market. COSMOPlat has demonstrated through numerous benchmark cases that its AI empowerment has moved beyond the “proof of concept” stage and is capable of delivering tangible economic benefits to enterprises.

    In the petrochemical industry, COSMOPlat has developed the world’s first petrochemical large model covering the entire industry chain, entire ecosystem chain, and entire value chain, which has been implemented in a large-scale petrochemical enterprise. Based on the model, the Company has developed 38 intelligent agents, such as the dynamometer intelligent assistant and the aldehyde separation tower process optimization agent, covering scenarios such as oilfield extraction, oil and gas refining and chemical processing, and production safety, with an average efficiency increase of 20%. Taking the dynamometer intelligent assistant as an example, based on the professional capabilities of whole-network search and the COSMOMind, this intelligent agent can “read and understand” dynamometer data of industrial equipment such as deep well pumps, accurately identify equipment failures and provide disposal suggestions, improving the efficiency of oil well equipment failure diagnosis and disposal by more than 50%; the aldehyde separation tower process optimization assistant integrates historical data and expert knowledge, enabling dynamic identification and adjustment suggestions for key parameters, providing decision-making assistance for operators, and significantly enhancing quality control precision and the product first-time conversion rate; the intelligent oil blending assistant quickly generates optimal blending schemes through interpolation algorithms and non-linear programming models, balancing product performance with green production requirements, fully validating the practical value of AI in the heavy chemical industry.

    In core manufacturing scenarios, COSMOPlat integrates AI technology throughout the entire chain of R&D, production, operation and maintenance. On the R&D side, taking a home appliance interconnected factory selected as a world “lighthouse factory” as a typical example, an AIGC virtual design assistant was introduced. Based on massive user preference data and an expert design asset library, it generated core solutions for three-drum washing machines. By simulating inner drum operation scenarios in advance to construct a dynamic balance optimization model, it solved the industry pain point of “collisions and interference” during multi-drum operation at the source; on the production side, the injection molding industrial intelligent agent, through deep learning of injection molding professional knowledge, equipment operation data, and process data, etc., precipitated the debugging methods that previously existed only in the minds of process technicians into various intelligent algorithms, ultimately forming professional injection molding knowledge Q&A and automated process parameter recommendation capabilities, building the most powerful “industrial brain” in the field of injection molding.

    In the energy sector, COSMOPlat’s energy-carbon model (COSMOMind for energy-carbon) is the first energy-carbon model originating from sustainable lighthouse factory practices. Based on this model, COSMOPlat offers enterprises and industrial park users an Energy-Carbon Management Platform and end-to-end smart-energy solutions, helping customers lower energy cost, improve utilization and advance green manufacturing. These cross-industry and multi-scenario success stories strongly demonstrate the practical effectiveness and replicability of COSMOPlat’s AI solutions.

    From an industrial cycle perspective, as the manufacturing system grows increasingly complex and cost and efficiency constraints intensify, enterprises’ demand for end-to-end digital and intelligent transformation will continue to rise, ensuring long-term certainty in industry development.

    COSMOPlat has pioneered the “space-air-ground integrated” technology system centered on large industrial models, with intelligent agents deeply embedded in production processes. This delivers a closed loop of perception, decision-making, and execution. Through multi-industry and multi-scenario validation, it demonstrates that AI possesses the capability to continuously generate industrial value. As application scenarios continue to expand, intelligent agents scale up, and the data flywheel effect intensifies, COSMOPlat is poised to translate its technological leadership into heightened platform stickiness and greater value per customer. Riding the wave of digital transformation, it is unlocking greater potential for value growth.

  • Everest Medicines Announces China NMPA Approval of VELSIPITY(R) for Adults with Moderately to Severely Active Ulcerative Colitis

    Everest Medicines today announced that China’s National Medical Products Administration (NMPA) has approved VELSIPITY(R) (etrasimod arginine tablets) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

    UC is a chronic, relapsing, non-specific inflammatory bowel disease. In China, the incidence and prevalence of UC are accelerating, with a clear trend toward younger patients. The patient population is projected to increase from approximately 0.98 million in 2025 to 1.50 million by 2031.There remains a critical need for therapies that offer sustained and comprehensive disease control.

    As a next-generation selective S1P receptor modulator, VELSIPITY(R) offers the potential for rapid onset of action, and long-lasting clinical remission and mucosal healing through an oral, once-daily regimen for adult patients with moderately to severely active UC.

    The approval was based on results from the Asian multicenter Phase 3 ENLIGHT UC study (ES101002) and the global ELEVATE UC Phase 3 program (ELEVATE UC 52 and ELEVATE UC 12). The ENLIGHT UC study is the largest Phase 3 trial of moderately to severely active UC in Asia completed to date, with 340 eligible subjects randomized to treatment with VELSIPITY(R) or placebo. The study results showed that, VELSIPITY(R) demonstrated statistically significant and clinically meaningful improvements across all primary and secondary efficacy endpoints during both the 12-week induction period and the 40-week maintenance period. The safety profile of VELSIPITY(R) was consistent with previous studies, with no new safety signals observed. The study confirms the efficacy and safety of VELSIPITY(R) in this population, with results published in The Lancet Gastroenterology & Hepatology.

    From a clinical value perspective VELSIPITY(R) is a once-daily oral therapy with rapid onset of action, strong mucosal healing efficacy, and a favorable safety profile. Prof. Chen Minhu, Academic Leader and Chief Expert of the Department of Gastroenterology at The First Affiliated Hospital of Sun Yat-sen University noted that UC is rapidly increasing in China and follows a relapsing course that significantly impairs quality of life and places a substantial burden on both patients and the healthcare system. Achieving mucosal healing is a widely recognized treatment goal in clinical guidelines, as it improves symptom control, reduces relapse risk, and supports long-term disease management.

    “UC treatment in China has long faced limited efficacy, high relapse rates, safety concerns, and inconvenient dosing. Despite available biologics and small-molecule therapies, unmet clinical needs persist,” said Prof. Wu Kaichun of the First Affiliated Hospital of AFMU, principal investigator of VELSIPITY(R)’s Asian clinical trial. “Its approval represents an important milestone and validation, providing patients with a novel treatment option and advancing UC management.”

    “Autoimmune diseases have long-term impacts on patients worldwide, with significant unmet clinical needs persisting both in China and globally,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “The approval of VELSIPITY(R) underscores the clinical value of innovative therapies for UC and reflects Everest Medicines’ sustained commitment to advancing drug development in line with international R&D standards. We look forward to expanding our global reach and providing patients with broader access to innovative treatment options.”

    “Its approval in China addresses a critical unmet medical need and introduces a novel oral therapy promoting deep mucosal healing,” said Mr. Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “We are committed to rapidly commercializing VELSIPITY(R) and working toward its inclusion in the National Reimbursement Drug List to further expand patient access and affordability, benefiting more patients across China.”

    The clinical value of VELSIPITY(R) has been recognized in leading international clinical guidelines. Following its inclusion in the American Gastroenterological Association (AGA) Clinical Practice Guideline in December 2024 as a first-line treatment for ulcerative colitis , VELSIPITY(R) was also included in the American College of Gastroenterology (ACG) Clinical Guideline Update in June 2025, with strong recommendations supporting its use for both induction and maintenance of remission in patients with moderately to severely active UC.

    In 2024, VELSIPITY(R) was included in the Catalogues of Guangdong Province on Drugs and Medical Devices from Hong Kong and Macao in Urgent Clinical Use in Nine Mainland Municipalities of the Guangdong-Hong Kong-Macao Greater Bay Area, making it available at designated hospitals across the region. The localized production project for VELSIPITY(R) was launched at the Jiashan manufacturing site in March 2025, supporting its future commercialization in China.

    The successful approval of VELSIPITY(R) further strengthens Everest Medicines’ product portfolio in the field of autoimmune diseases and also forms a critical part of the 2030 strategy of the Company. This strategy is built on a dual-engine model of business development partnerships and in-house R&D, aiming to generate predictable value through commercialization while building long-term growth momentum through sustained innovation, thereby supporting pipeline continuity and sustainable development.

    The Company has established a portfolio of three commercial products and continues to develop a fully integrated commercial platform covering the entire product lifecycle.The Company targets annual revenue exceeding RMB10 billion by 2028, and RMB15 billion by 2030 (including approximately RMB9 billion from the existing pipeline and approximately RMB6 billion from newly in-licensed assets). Revenue is expected to grow at a compound annual growth rate (CAGR) of over 50% from 2025 to 2030 and to remain above 15% thereafte.Over the same period, the number of commercial products is expected to exceed 20, including NEFECON(R), VELSIPITY(R), XERAVA(R), Lerodalcibep and MT1013.

    Industry observers widely expect VELSIPITY(R) to become Everest’s next blockbuster product, with analysts projecting peak sales of up to RMB 5 billion. As VELSIPITY(R) realizes its commercial potential, Everest’s revenue mix and growth trajectory are expected to strengthen further. Looking ahead, Everest Medicines will continue to focus on therapeutic areas with significant unmet clinical needs. Leveraging its established commercialization capabilities and in-house R&D, the company aims to accelerate the launch of innovative therapies with global competitiveness, drive sustainable growth, and create greater health value for patients and society.

  • Distinct Healthcare Successfully Listed on HKEX, Bolstered by Premium Customer Base and All-Star Cornerstone Investors

    On February 6, Distinct Healthcare Holdings Limited (Distinct Healthcare or the Company, Stock Code: 2677.HK), a leading player in China’s mid-to-high-end consumer healthcare services market, was successfully listed on the main board of the Hong Kong Stock Exchange, emerging as a high-quality and rare private healthcare gem in the Hong Kong stock market. This marks the beginning of a new chapter in the Company’s scaled and high-quality development.

    On its debut, Distinct Healthcare delivered a standout debut, opening sharply higher at HK$81 per share (a 35.23% premium to the offer price), well above the offer price—an indication of strong capital market recognition of the Company’s growth potential. The active trading and high investor enthusiasm further corroborate the market’s firm confidence in the consumer healthcare services sector and the Company’s core value.

    Possessing a Large Customer Base with Continuously Improving Profitability
    As the third-largest provider of private mid- to high-end healthcare service in China, Distinct Healthcare has always adhered to its patient-oriented core principle, placing patient well-being at the forefront. This approach has enabled the Company to gradually build a large and high-quality patient base, leading the industry in both user scale and return rate.

    From 2022 up to the eight months ending 31 August 2025, the total number of patients served by its healthcare institutions in China rose from 162,393 to 212,180, and the total number of paid patient visits of its healthcare service institutions and tele-healthcare service platform grew from 529,829 to 642,132.

    Patient loyalty has continued to rise, with the patient return rate steadily climbing. In 2022, 2023, 2024 and the eight months ended 31 August 2025, the patient return rates reached 75.7%, 78.2%, 80.0% and 82.7%, respectively. This robust growth is a strong testament to the market and patients’ high recognition of Distinct Healthcare’s service quality.

    Leveraging its large and high-quality customer base and the advantages of its standardized medical services, Distinct Healthcare has achieved steady business growth “without relying on medical insurance subsidies or excessive marketing expenditure”. Financial data shows the Company’s total revenue increased steadily from RMB473 million in 2022 to RMB959 million in 2024, doubling its revenue in two years and achieving a compound annual growth rate (CAGR) of 42.3%, demonstrating strong growth momentum.

    In terms of profitability, the Company achieved a critical milestone by turning profitable in 2024, with an adjusted net profit of RMB10.7 million. This represents a qualitative leap from scale-driven growth to profitability-driven growth.

    Strong Line-up of Cornerstone Investors and Clear Strategic Plan Support High-Quality Development
    Distinct Healthcare has attracted a strong roster of cornerstone investors in this IPO, including Health Vision, Kingmed Diagnostics, Mininglamp Technology, and Galaxy Dynasty. Together, they subscribed for a total of approximately HK$90.7876 million. The active participation of these renowned, high-quality institutional investors fully reflects their high recognition of Distinct Healthcare’s core competitiveness, business model, and future development prospects, and will also provide powerful resource support and brand endorsement for the Company’s subsequent development, helping it to further expand its industry influence.

    Regarding the use of IPO proceeds, Distinct Healthcare has formulated a clear strategic plan to ensure the proceeds are effectively deployed to support the Company’s high-quality growth. Approximately 35% of the net proceeds will be allocated to digitalization and intelligent upgrades. By building a professional talent pool for medical AI applications, establishing strategic partnerships with leading research institutions and technology companies and making external procurements, while leveraging internal IT and data technology departments to iteratively optimize existing IT systems, the Company will deploy advanced AI technologies, optimize medical service workflows and enhance diagnostic efficiency as well as operational effectiveness.

    Approximately 30% of the net proceeds will be used for service network expansion and upgrades, primarily focusing on enhancing the diagnostic environment and equipment at existing medical service institutions. It will also advance the layout of new institutions, including relocating an existing institution in Shenzhen and establishing new institutions in key cities such as Hangzhou and Shanghai, thereby further expanding and improving service coverage in key domestic regions.

    Approximately 25% is earmarked for strategic mergers and acquisitions, acquire high-performing medical service institutions with strong synergies in first-tier and new first-tier cities when suitable opportunities arise, aiming to rapidly expand market share and strengthen regional competitiveness. The remaining approximately 10% will be used as working capital and for general corporate purposes, providing stable financial support for daily operations and business expansion.

    This clear strategic roadmap not only charts a clear course for the Company’s future growth, effectively enhancing its core competitiveness and sustainability, but will also further reinforce its leading position in China’s private mid-to-high-end healthcare sector. It will help propel the Company to new heights, achieving its long-term goals of scaled and high-quality development.

    This successful listing on HKEX represents a significant milestone in Distinct Healthcare’s development journey, marking its official entry into a new phase driven by both “capital and industry”. It will further elevate the Company’s brand influence and financing capabilities, injecting powerful momentum for its future growth.

    Moving forward, Distinct Healthcare will remain true to its founding aspirations, staying focused on the mid-to-high-end healthcare services segment. It will continue to enhance medical service quality and patient experience, further unlock its growth potential and deliver sustainable long-term returns to its shareholders.

  • Muyuan Foods Makes Hong Kong Debut Today: Strong Cornerstone Investor Backing Fuels Rapid Earnings Growth, Embarking on New Journey of Internationalization

    On 6 February, Muyuan Foods Co., Ltd. (Muyuan Foods or the Company, Stock Code: 2714.HK), a global leader in the pork industry, officially listed on the Main Board of The Stock Exchange of Hong Kong Limited today, marking the beginning of a new chapter in the Company’s international development.

    Powerful Cornerstone Investors Underscore Muyuan’s Industry Leadership
    For this Hong Kong IPO, Muyuan Foods successfully attracted a prestigious lineup of cornerstone investors, including Charoen Pokphand Foods, Wilmar International Limited (Wii Pte. Ltd. and HPRY), Sinochem Hong Kong, Hong Kong Henan Agri

    International, FIL Investment, RBC Global Asset Management (Asia) Limited and Ping An Life Insurance Company of China, Ltd., and other renowned institutions—14 in total—with combined subscription amounting to US$685 million. This formidable cornerstone investor group not only provides the Company with stable financial support but also brings abundant industrial resources and an international perspective, laying a solid foundation for its subsequent global expansion and valuation enhancement.

    As a technology-driven pork industry leader, Muyuan Foods has deep expertise cultivated over many years in the industry and has established a uniquely advantageous vertically integrated business model. Its operations comprehensively cover the entire pork industry chain, including hog breeding, hog farming, feed production, as well as slaughtering and meat production. Leveraging synergistic advantages across the entire chain, the Company has steadily maintained its leadership position in the hog farming industry.

    According to statistics from Frost & Sullivan, since 2021, measured by hog production capacity and hog sales volume, Muyuan Foods has become the world’s largest hog farming enterprise. Its hog sales volume has ranked first globally for four consecutive years, solidifying its position as the industry leader. In terms of market share, the Company’s global market share steadily increased from 2.6% in 2021 to 5.6% in 2024. As of 2024, this market share already exceeded the combined market share of the world’s second to fourth largest participants in the hog farming industry, further widening the gap with peers and continuously highlighting its core competitiveness.

    Steady Earnings Growth Maintained; Active Overseas Market Expansion Strengthens Competitiveness
    Relying on its full industry chain layout and efficient operational management, Muyuan Foods has maintained steady earnings growth in recent years, with profitability continuously improving, demonstrating the Company’s operational resilience through solid business data. Data shows that the Company’s revenue scale grew steadily from RMB124.826 billion in 2022 to RMB137.947 billion in 2024. Net profit surged significantly from RMB14.933 billion in 2022 to RMB18.925 billion in 2024, indicating remarkable growth and continuously optimized profitability. Entering 2025, the Company’s growth momentum further accelerated. In the first nine months of 2025, the Company achieved operating revenue of RMB111.790 billion, a year-on-year increase of 15.5%, and realized a net profit of RMB15.112 billion, a substantial year-on-year increase of 34.4%. The double-digit growth in both revenue and net profit fully demonstrates the Company’s strong development momentum and favorable profit outlook.

    While consolidating its leading position in the domestic market and achieving rapid self-development, Muyuan Foods has consistently anchored its global development strategy, actively expanding into overseas markets. Using the export of technology and equipment as a key approach, it empowers the upgrading of the global hog farming industry and builds an international farming ecosystem. In 2024, the Company entered into a deep strategic partnership with BAF Vietnam Agriculture, providing services including hog house design, biosecurity management, odor control solutions and smart hog farming to help its partner optimize farming efficiency, reduce operational costs, and practice environmentally responsible farming.

    The smooth progress of this cooperation marks a crucial first successful step for Muyuan Foods in its global layout, accumulating valuable experience for subsequent overseas market expansion. On the other hand, leveraging the vast potential of overseas markets, Muyuan Foods will further achieve optimized resource allocation and efficient synergy on a global scale, continuously broadening its corporate growth boundaries and diversifying profit sources, thereby solidifying its core advantages and enhancing comprehensive competitiveness.

    Overall, the successful listing in Hong Kong not only signifies that Muyuan Foods has formally entered a new stage of internationalized development, establishing an important bridge connecting global capital and resources, but also indicates that the Company’s operational management level, industry competitiveness, and development potential have gained broad recognition from the international capital market. In the future, Muyuan Foods will seize this listing opportunity, adhere to the philosophy of technology-driven and green development, continue to deepen its involvement in the entire pork industry chain, constantly strengthen its core competitiveness, steadily advance its global layout, further consolidate its position as the global leader in the hog farming industry, and open up broader growth space. Its future development is worthy of market anticipation.

  • TANAKA PRECIOUS METAL TECHNOLOGIES establishes total solutions system for contract manufacturing of various test kits including in vitro diagnostics

    Expanding production capacity by introducing automated equipment reduces manufacturing costs and shortens delivery times

    TOKYO, Feb 5, 2026 – (JCN Newswire) – TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd. (Head Office: Chuo-ku, Tokyo; Representative Director & CEO: Koichiro Tanaka), a company engaged in the industrial precious metals business of TANAKA, announced today that it has established a total solution system capable of supporting all processes in the contract manufacturing business for various test kits including in vitro diagnostics.

    Until now, TANAKA has been responsible primarily for processes from developing and manufacturing test kits to bulk production of extraction buffer. At this time, TANAKA established dedicated production lines for the dispensing and packaging of extraction buffer, creating a system that enables it to complete all processes in-house from development to manufacture of final products. This enables TANAKA to reduce costs and the time for external outsourcing and transportation, making it possible to deliver high-quality products in shorter times.

    In addition, TANAKA will seek to expand production capacity and shorten lead times even further by introducing additional state-of-the-art automatic assembly lines and extract dispensing equipment with a target of March 2026.

    TANAKA's Total Solution System
    TANAKA’s Total Solution System

    Flexible responses achieved through reinforced integrated production system

    By establishing this total solution system, TANAKA will be able to provide comprehensive contract services covering all processes from test kit development and manufacturing to bulk production, dispensing, and packaging of extraction buffer. This will enable TANAKA to continuously support customers from the development stage through mass production while also accommodating request for individual processes such as extraction buffer dispensing only.

    By bringing production processes entirely in-house, TANAKA will further reinforce stable supply and quality control.

    A track record in the development of diagnostic test kits across a wide range of disease areas and examples of deployment

    TANAKA offers in vitro diagnostics for a wide range of infectious diseases including respiratory tract infections, such as influenza and COVID-19, as well as dengue and ZIKA viruses. These test kits are compatible with various sample types such as saliva, blood, and urine, and support rapid and accurate testing in clinical settings.

    Respiratory Tract Infections

    Mosquito-Born Infectious Diseases

    Obstetrics

    ・ Influenza virus
    ・ Adenovirus
    ・ RS virus
    ・ Human meta-virus
    ・ COVID-19
    ・Group A beta hemolytic Streptococcus (Streptococcus pyogenes)

    ・ Dengue virus
    ・ Zika virus
    ・ Chikungunya virus

    ・ Pregnancy testing

    Examples of Disease Areas That TANAKA Deploys Tests For

    Technical foundations and future outlook

    TANAKA started research and development of in vitro diagnostics around 2006 and has accumulated technologies centered on nano-colloidal gold (Au). It possesses a diverse range of technologies that support the enhancement of reagent performance using immunochromatographic assay, including protein immobilization technology, non-specific absorption expression technology, and antigen-antibody reaction enhancement technology, TANAKA provides contract manufacturing of high-quality test kits that leverage these technologies in accordance with the ISO 13485 system.

    Going forward, TANAKA will leverage this total solution system to develop new diagnostics in collaboration with partner companies, while contributing to solutions to social issues and advancement of the field of medicine.

    About TANAKA

    Since its foundation in 1885, TANAKA has built a portfolio of products to support a diversified range of business uses focused on precious metals. TANAKA is a leader in Japan regarding the volume of precious metals it handles. Over many years, TANAKA has manufactured and sold precious metal products for industry and provided precious metals in such forms as jewelry and assets. As precious metals specialists, all Group companies in Japan and worldwide collaborate on manufacturing, sales, and technology development to offer a full range of products and services. With 5,591 employees, the group’s consolidated net sales for the fiscal year ended December 2024 were 846.9 billion yen.

    TANAKA Industrial Precious Metal Materials Portal
    https://tanaka-preciousmetals.com

    Product inquiries
    TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd.
    https://tanaka-preciousmetals.com/en/inquiries-on-industrial-products/

    Press inquiries
    TANAKA PRECIOUS METAL GROUP Co., Ltd.
    https://tanaka-preciousmetals.com/en/inquiries-for-media/

    Press release: https://www.acnnewswire.com/docs/files/20260205_EN.pdf

    Disclaimer:

    ANY EXPRESS WRITTEN WARRANTY THAT TANAKA MAY ISSUE, IS THE SOLE AND EXCLUSIVE WARRANTY AS TO TANAKA’S MATERIALS AND PRODUCTS, EXTENDS ONLY TO THE INITIAL PURCHASER FROM TANAKA OR ITS AUTHORIZED DISTRIBUTOR, IS NOT TRANSFERABLE OR ASSIGNABLE, AND IS EXPRESSLY IN LIEU OF AND TANAKA EXPRESSLY DISCLAIMS TO THE EXTENT PERMISSIBLE UNDER APPLICABLE LAW ANY OTHER WARRANTY, ORAL OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY ORAL OR IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR PARTICULAR PURPOSE.

    TANAKA SHALL NOT BE LIABLE FOR ANY INCIDENTAL, SPECIAL, OR CONSEQUENTIAL LOSS, DAMAGE, OR EXPENSE (INCLUDING, WITHOUT LIMITATION, LOST PROFITS) DIRECTLY OR INDIRECTLY ARISING FROM THE SALE, INABILITY TO SELL, USE, OR LOSS OF USE OF ANY PRODUCT. NO ORAL OR WRITTEN INFORMATION OR ADVICE GIVEN BY TANAKA, ITS EMPLOYEES, DISTRIBUTORS, DEALERS, OR AGENTS SHALL INCREASE THE SCOPE OF ANY WARRANTY OR CREATE ANY NEW WARRANTIES.

    THE LIMITATIONS AS STATED HEREIN SHALL NOT PRECLUDE ANY LIABILITY WHICH UNDER APPLICABLE PRODUCTS LIABILITY LAW CANNOT LEGALLY BE PRECLUDED BY CONTRACT OR OTHERWISE.

     

    NEVER USE THIS TEST KIT AS THE ONLY GUIDE TO MANAGE YOUR CONDITION OR ILLNESS. CONSULT YOUR HEALTHCARE PROVIDER IF YOUR SYMPTOMS PERSIST OR BECOME MORE SEVERE, OR IF YOU ARE CONCERNED AT ANY TIME.

  • HKTDC to host world’s largest one-stop jewellery marketplace

    – New Hard Pure Gold Pavilion showcases breakthrough gold technologies

    Organised by the Hong Kong Trade Development Council (HKTDC), the world’s largest one-stop jewellery marketplace will return in early March under its proven “Two Shows, Two Venues” format. The 12th Hong Kong International Diamond, Gem & Pearl Show will take place from 2 to 6 March at AsiaWorld-Expo and will feature a wide range of jewellery raw materials. Also, the 42nd Hong Kong International Jewellery Show will be held from 4 to 8 March at the Hong Kong Convention and Exhibition Centre and will showcase finished jewellery pieces.

    Jenny Koo, Deputy Executive Director of the HKTDC, said: “This year’s twin jewellery shows bring together some 4,000 exhibitors from over 40 countries and regions, with 70% coming from outside Hong Kong. Exhibitor participation from Brazil, United Arab Emirates and India has expanded, and Uzbekistan joins for the first time. The HKTDC presents the world’s largest one-stop jewellery marketplace to highlight Hong Kong’s status as an international trade capital and jewellery sourcing hub.”

    In reviewing the global jewellery market, Hong Kong’s export volume of premium jewellery to ASEAN recorded a 51% increase, while exports to the United Kingdom, Australia and Switzerland grew year-on-year by 36%, 28% and 10% respectively.

    Over 40 themed pavilions, including a new Hard Pure Gold Pavilion
    The twin shows attract strong global industry support, with exhibitors participating from over 40 regional and industry pavilions. Participating regions include Chinese Mainland, Taiwan, India, Israel, Korea, Myanmar, Singapore, Sri Lanka, Thailand, Uzbekistan, Belgium, Germany, Italy, Spain, Türkiye, Brazil, Colombia, Mexico and the United States, etc.

    The World Gold Council debuts the Hard Pure Gold Pavilion, featuring a total of 11 exhibitors from Chinese Mainland, showcasing innovative gold craftsmanship to the global market. The pavilion aims to leverage the fairs as a springboard for international expansion.

    The Hong Kong Watch Manufacturers Association Ltd will participate as a pavilion for the first time, while the Zhushan Turquoise pavilion from Hubei will also make its debut. Other returning participants include the Tanzanite Foundation, the International Colored Gemstone Association (ICA), the Asia Pacific Creator Association, and the Asia Jewellery Culture Design and Crafts Association. The Hong Kong Jewellery & Jade Manufacturers Association will once again join forces with the Italian Exhibition Group (IEG) to present advanced jewellery manufacturing equipment and technologies.

    International brands in the spotlight
    The Hall of Fame at the Hong Kong International Jewellery Show makes a highly anticipated return this year with more than 40% expansion in scale. It will welcome renowned international jewellery brands and help enhance global brand exposure. Turkish diamond jewellery brand Zen Diamond (Booth: CEC 3B-C12) presents diamond ring collections featuring exquisite cutting techniques. At the Hall of Extraordinary, Hong Kong exhibitor Continental Diamond Company (Booth: CEC GH-C07) showcases an 18K white and rose gold ring set with blue and light pink diamonds. Another Hong Kong exhibitor, Unique Brilliant Ltd (Booth: CEC GH-C13), unveils a necklace and earring set, the rubies display the coveted “pigeon blood red” colour.

    Oriental Aesthetics showcases cultural heritage craftsmanship
    This year’s shows will feature numerous jewellery pieces inspired by Asian culture and heritage. Chinese Mainland exhibitor, Guangdong JIABAO Pavilion Jewellery (Hong Kong) Company Ltd (Booth: CEC GH-A16) presents an 18K gold, handmade filigree butterfly brooch, made with national intangible heritage craft, with each piece taking over four months to complete. Another Chinese Mainland exhibitor, Shenzhen Meifei Precious Metals Co Ltd (Booth: CEC 3E-E02), brings a “Palatial Modern Chinese Style” jewellery series incorporating six traditional gold techniques, blending heritage craftsmanship with modern jewellery design.

    In recent years, hard pure gold technology has gained strong momentum in Chinese Mainland. Its high purity and enhanced hardness enable lighter, more durable designs with modern aesthetics. A seminar organised by the World Gold Council will examine the latest developments in the global gold market and hard pure gold technology.

    During the fairs, a series of events spotlighting Oriental aesthetics in jewellery will be staged. Hong Kong International Fashion Chuk Kam Jewellery Design Competition 2026, organised by the Jewellers’ and Goldsmiths’ Association of Hong Kong Limited, encourages designers to create commercially viable and culturally rich gold jewellery for young consumer markets in ASEAN and the Middle East. Its award presentation ceremony will be held during the fairs.

    In addition, the inaugural International Fei Cui Jewellery Design Competition 2026, organised by the Hong Kong Jade Association, will also host its awards presentation during the fairs.

    Creative design sets the trend
    Innovative and trend-driven products help the industry stand out. Austy Lee Company Ltd (Booth: CEC 1E-F32) introduces bangles inspired by zebra patterns for the Year of the Horse. Designer Galleria welcomes new exhibitor Zheng Hong Collective (Booth: CEC 1CON-067A), featuring a brooch whose movable wings and tail sway with the wearer.

    The 27th Hong Kong Jewellery Design Competition, themed “Pure Elegance – Natural Beauty”, returns to nurture creative talent. Local students and industry professionals interpret the beauty of nature and their design stories through their creations, highlighting the diverse facets of jewellery design. Winning designs will be announced during the fairs.

    Rare treasures dazzle across both shows
    As always, the twin shows offer buyers an outstanding selection of antique and rare jewellery. At the Hong Kong International Jewellery Show, Hong Kong exhibitor Baroque Antique & Jewellery Limited (Booth: CEC CH-F13) presents a 1970s Buccellati pink sapphire suite, while World Coins Co., Ltd. (Booth: CEC CH-N12) showcases a 19th-century Italian bi-colour enamel diamond piece preserved in its original box for over 100 years. At the Hong Kong International Diamond, Gem & Pearl Show, German exhibitor Caram e.K. (Booth: AWE 8-F05) features an 18.98-carat AGL-certified natural pink sapphire, while Canadian exhibitor Korite Ammolite Ltd. (Booth: AWE 8-F35) displays an 18K gold AA-grade ammolite and diamond necklace.

    The Hong Kong International Jewellery Show will also host a seminar titled “The Origins of Style: Tracing the Imprint of Time and Craftsmanship.” This seminar will invite British historian and jewellery authority Dr. Jack Ogden to speak. He will provide an in-depth analysis of the evolution of jewellery craftsmanship and changes in aesthetic tastes across different eras.

    Over 20 forums on hot topics including AI and digital marketing
    More than 20 seminars and networking sessions will be held, covering industry trends, digital marketing and jewellery technologies. A session will examine how artificial intelligence moves from design to commercialisation to drive the development of the jewellery industry. There will also be seminars where influencers share how to leverage e-commerce platforms to enhance jewellery brand visibility, boost sales, and share practical experience, to help the industry accelerate the integration and synergy between online and offline channels.

    Business opportunities and industry exchange
    The exhibition attracts major international jewellery retail chains, as well as high-end, affordable luxury, and designer jewellery brands from around the world for sourcing. It creates business opportunities for both buyers and sellers while fostering industry exchange.

    The HKTDC has partnered with the Hong Kong Tourism Board and local enterprises to provide exclusive buyer privileges. These offers include dining, air tickets, and hotels, enabling buyers to enjoy Hong Kong’s unique charm while attending the fairs. The HKTDC will arrange free shuttle bus services between AsiaWorld-Expo and urban areas (including the Hong Kong Convention and Exhibition Centre in Wan Chai). For details, please refer to the fair’s official website.

    Combining online and offline services to facilitate sourcing
    The shows use the EXHIBITION+ hybrid format. In addition to on-site procurement, the HKTDC’s AI-powered “Click2Match” will provide online business-matching for exhibitors and buyers from 23 February to 13 March. On-site buyers can use “Scan2Match” to scan exhibitors’ QR codes and continue discussions with exhibitors online during or after the show. To ease the buyer admission process, the HKTDC Marketplace App and the official websites of the two shows provide online verification functions. Buyers need only register through these platforms and upload a photo and valid identification to obtain a verified eBadge for direct entry, greatly reducing queuing times for onsite registration and verification and enhancing sourcing efficiency.

    Photo download: https://bit.ly/4ayrcAo

    image

    image

    image

    image

    HKTDC Media Room: https://mediaroom.hktdc.com/en

    Media enquiries
    Please contact HKTDC’s Communication & Public Affairs Department:

    Winnie Kan Tel: (852) 2584 4055 Email: winnie.wy.kan@hktdc.org
    Katy Wong Tel: (852) 2584 4524 Email: katy.ky.wong@hktdc.org
    Jane Cheung Tel: (852) 2584 4137 Email: jane.mh.cheung@hktdc.org

    About HKTDC
    The Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong’s trade. With over 50 offices globally, including 13 in Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus.

  • Banle Group Hosts Inaugural ESG Forum with Industry Leaders, Pioneering Green Shipping Solutions Amid Global Decarbonization Push

    Banle Group (Banle or the Group), a leading Asia-Pacific marine fuel logistics provider, hosted its landmark inaugural ESG Forum — Charting the New Horizon: Powering Green Shipping with Sustainable Fuels — uniting top maritime executives, financiers, legal experts, and climate scientists to address the shipping industry’s urgent decarbonization challenges on February 2.

    Speaker Lineup Tackles Critical Issues
    The forum featured exclusive insights from:

    • Dr. Teck Lim Chia, Chairman and CEO of Banle Group
    • Ms. Karen Cheah Yee-Lynn, Independent Director of Banle Group, Partner of Chooi & Company, Immediate Past President of the Malaysian Bar and EXCO Member of LAWASIA
    • Mr.Matt Liu Ming-Hsuan, SVP Capital Solutions, Cathay United Bank
    • Dr.Wilson Cheung Wai-yin, Polar Explorer, Glaciologist and Policy Advisor, Polar Research and Expedition Consultancy
    • Ms.Rebecca Zhang, Senior Manager Sustainable Finance, Commercial Banking, Hong Kong, HSBC

    The forum served as a dynamic platform for thought leadership and dialogue, featuring a series of presentations addressing critical topics such as the impact of climate change on global shipping, evolving sustainability-related regulations, and innovative green and sustainability-linked financing solutions.

    Dr.Teck Lim Chia addressed in the keynote speech, “The global shipping industry stands at a pivotal moment. Rapid regulatory changes, geopolitical tensions, climate challenges, and technological advancements are reshaping the landscape at unprecedented speed. Yet, we are dedicated to fostering a collaborative environment where stakeholders can come together to share insights and develop strategies for a more sustainable future.”

    On the forum, Ms.Karen Cheah talked about how ESG has become a legal, economic, and moral imperative to safeguard planetary health – and how governments, businesses, courts, and capital markets at an international level must work together holistically to turn sustainability from aspiration into measurable action. She said, “We must establish planetary health metrics to track environmental, health, and risk impacts on all of us. This requires not only a measurement to gauge our progress but also a strategic plan to communicate these metrics, drive global awareness, and educate society at large. Moreover, we must integrate these metrics into governance structures at organizational, domestic, national, and international levels. We must engage in responsible business practices aligned with ESG components and ensure a robust framework for planetary health is implemented globally. Once we align collectively, we can systemize this framework for lasting impact.”

    Mr.Matt Liu shared his insight on integrating ESG features into financing strategies, “Green loans excel when companies have a clear, specific investment plan. Sustainability-Linked Loans (SLLs) operate under a distinct logic: their Key Performance Indicators (KPIs) must reflect material sustainability issues, be measurable, traceable, and independently verifiable. Crucially, Sustainability Performance Targets (SPTs) must balance ambition with feasibility, remaining achievable within the company’s operational capacity. Unlike green loans, SLLs do not restrict proceeds to green activities; instead, they demonstrate sustainability commitment through performance-linked financial mechanisms. Beyond loans and bonds, nearly all liability-style financial products can now integrate green or sustainability elements. This flexibility allows companies to align financing with sustainability goals while maintaining operational practicality, driving both environmental progress and financial innovation.”

    Dr.Wilson Cheung addressed his dedication to geoscientific education and advocacy, and talked about the responsible opportunities for the shipping industry, “Responsible opportunities in the shipping industry begin with recognising that the Arctic is not only a shortcut, but also a living homeland and a fragile climate regulator for the planet. New polar sea routes can reduce transit time and fuel use, yet they cross waters where infrastructure is scarce, ecosystems are vulnerable, and Indigenous communities depend on sea ice for culture and survival. True leadership means investing in cleaner fuels, ice-class vessels, and robust search-and-rescue capacity, while strictly limiting black carbon emissions and respecting international polar regulations. It also means listening to local knowledge that has guided safe travel on ice for thousands of years and integrating that wisdom with modern science and satellite data. If the industry embeds ESG principles into every Arctic voyage, these emerging routes can become a model of responsible innovation rather than a new frontier of unchecked risk.”

    Ms.Rebecca Zhang shared recent shipping industry transition trends from a sustainable finance perspective: “Regulations are constantly evolving, and so must global efforts to tackle climate change and make maritime transport more sustainable. Innovative solutions are emerging, and shipowners are exploring alternative energy options such as biofuels, bio-LNG, and bio-gas. The development of clean technologies is accelerating the industry’s systemic shift towards sustainability.”

    The forum concluded with a lively and interactive networking among participants, who exchanged ideas and reaffirmed their collective commitment to advancing sustainable practices throughout the shipping industry.

    Banle Group’s sustainability leadership by example through its operational practices was prominently showcased, highlighting its ongoing efforts to spearhead industry decarbonization and responsible practices. Through initiatives like its participation in the EcoVadis rating system and advocacy for diverse sustainable marine fuels, Banle continues to drive meaningful transformation across the shipping sector.

    Looking ahead, the Banle Group remains committed to hosting future forums that foster dialogue, innovation, and collaboration for a more sustainable maritime ecosystem.

    Dr.Teck Lim Chia added: “This is just the beginning. Banle will continue driving practical decarbonization solutions for our industry and clients.”

    For more information about Banle Group and its sustainability initiatives, please visit www.banle-intl.com.

    Photo Caption 1: Dr. Teck Lim Chia (centre) presented souvenirs to all speakers and panelists as a token of appreciation.


    Photo Caption 2: Panelists engaged in a discussion on the theme: “Charting the New Horizon: Powering Green Shipping with Sustainable Fuels”. Ms. Karen Cheah (left) served as moderator, guiding the discussion while also contributing her insights as a panelist.

    Photo caption 3: Attendees gathered at the ESG Forum, showcasing a shared commitment to sustainable practices and innovative solutions in the shipping industry.

    About Banle Group
    CBL International Limited (Nasdaq: BANL) is the listing vehicle of Banle Group, a reputable marine fuel logistics company based in the Asia Pacific region that was established in 2015. We are committed to providing customers with a one-stop solution for vessel refueling, which is referred to as bunkering facilitator in the bunkering industry. We facilitate vessel refueling mainly through local physical suppliers in 65 major ports covering Belgium, China, Hong Kong, India, Japan, Korea, Malaysia, Mauritius, Panama, the Philippines, Singapore, Taiwan, Thailand, Turkey and Vietnam. The Group actively promotes the use of sustainable fuels and has been awarded the ISCC EU and ISCC Plus certifications, as well as EcoVadis Silver Medal.

    For more information, please visit: https://www.banle-intl.com.

  • Annature Launches 21 CFR Part 11 Compliant Digital Signatures to Support FDA-Regulated Organisations

    Annature, Australia’s leading eSignature and Identity verification provider, has announced the release of its 21 CFR Part 11 compliant electronic signature module, enabling organisations operating in FDA‑regulated environments to execute electronic records with confidence.

    The new capability ensures Annature customers can meet the U.S. Food and Drug Administration’s requirements for electronic records and electronic signatures under 21 CFR Part 11, a regulation that governs data integrity, signer authentication, and auditability across industries such as life sciences, pharmaceuticals, biotechnology, and clinical research.

    The release has been driven by growing demand from U.S.-based and multinational organisations seeking a modern, compliant alternative to legacy eSignature platforms. Several customers operating in regulated environments have already transitioned to Annature as part of broader digital transformation initiatives, prompting the company to formally introduce Part 11 support as part of its international product roadmap.

    “As we continue to grow globally, it’s critical that Annature supports the regulatory frameworks our customers operate under,” said Corey Cacic, CEO of Annature. “Our 21 CFR Part 11 module allows organisations subject to FDA requirements to use Annature with confidence, knowing their electronic signatures meet the necessary compliance standards.”

    The module introduces controls aligned with Part 11 expectations, including secure signer authentication, tamper‑evident audit trails, and strong linkage between electronic signatures and the records they relate to. These features ensure electronic signatures executed through Annature can be relied upon in regulated workflows and during regulatory review.

    Kim Steel, Founder and Managing Director of SAPRO – a boutique CRO supporting niche biotech and pharmaceutical companies with commercially sponsored Phase I-III full-service clinical trials has welcomed the release.

    “For organisations operating in regulated environments, compliance with 21 CFR Part 11 is not optional – it is fundamental,” said Steel. “It is encouraging to see Annature, an Australian technology provider supporting international regulatory requirements that are critical to our industry and our clients. Solutions like this enable sponsors to operate confidently on a global stage, without reliance on outdated or overly complex legacy systems, while remaining inspection and audit-ready at all times.”

    The launch further strengthens Annature’s position as a global‑ready eSignature platform, supporting organisations that operate across jurisdictions with varying compliance obligations. The 21 CFR Part 11 module is available now and can be enabled for customers who require FDA‑compliant electronic signatures.

    About Annature
    Annature is Australia’s leading eSignature and Identity verification provider, trusted by over 6,700 businesses. With a Pay as you go model and deep integration across the business app ecosystem, Annature delivers secure, affordable, and locally supported solutions for professionals across the country. Annature’s growing product suite also includes integrated payments and compliance features designed to support both domestic and international regulatory requirements.

    https://www.annature.com.au

    CONTACT:
    Name: Corey Cacic
    Email: corey@annature.com.au

    SOURCE: Annature

  • Everest Medicines Announces Exclusive License Agreement with Micot to Commercialize MT1013

    Everest Medicines (HKG: 1952, Everest, or the Company), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an exclusive license agreement with Shaanxi Micot Pharmaceutical Technology Co., Ltd. (Micot) to commercialize MT1013, the world’s first-in-class dual-targeting receptor agonist polypeptide that simultaneously targets the Calcium-Sensing Receptor (CaSR) and the Osteogenic Growth Peptide (OGP) receptor and is primarily developed with Secondary Hyperparathyroidism (SHPT) as its leading indication, in China and Asia-Pacific (excluding Japan).

    According to the agreement, Everest Medicines will pay Micot an upfront payment of RMB 200 million and potential regulatory and commercial milestone payments of up to RMB 1,040 million. MT1013 has entered Phase III clinical trial in China and the relevant development expenses will be covered by Micot. The strategic collaboration is expected to complement Everest Medicines’ existing renal pipeline and drive operating synergies, further strengthen the Company’s commercial product portfolio, and solidify its leading position in renal and autoimmune diseases in Asia, which are key therapeutic areas of focus. The collaboration will also expand the Company’s nephrology portfolio from IgA nephropathy to a broader range of chronic kidney diseases (CKD).

    MT1013 is the world’s first-in-class dual-targeting receptor agonist polypeptide internally developed by Micot. The Phase II data were presented orally and in a Late-Breaking session at the 2025 American Society of Nephrology (ASN) Annual Meeting. MT1013 uniquely combines the calcium-sensing receptor (CaSR) and the osteogenic growth peptide (OGP) receptor, addressing imbalances in parathyroid hormone (PTH), calcium, and phosphate metabolism. This innovative dual mechanism allows MT1013 to control SHPT and related bone metabolism disorders at the source, and to actively promote bone formation and repair through direct activation of osteogenic pathways, representing a therapeutic innovation shift from indirect inhibition of bone resorption to active stimulation of bone formation.

    Clinical studies have demonstrated that MT1013 acts rapidly, with strong and durable efficacy, and has a favorable safety profile in patients with CKD on maintenance hemodialysis with SHPT. It has shown potential advantages over current therapies in achieving comprehensive endpoints, including control of intact parathyroid hormone (iPTH), serum calcium, and phosphate levels, as well as improving calcium-phosphate balance and offering potential cardiovascular benefits. MT1013 is currently being evaluated in a Phase III clinical trial in China for this patient population, with over 50% of the target enrollment already achieved.

    SHPT is one of the most common and serious complications in patients with CKD. It causes disturbances in calcium and phosphate metabolism, elevated PTH levels, bone disorders, and vascular calcification, which substantially increase the risk of fractures, cardiovascular events, and mortality. SHPT is therefore an important factor influencing outcomes and prognosis in patients with CKD. With the global prevalence of CKD continuing to rise, the unmet medical need for effective SHPT therapies is also growing. Data indicate that the global population of patients with CKD has increased from 905.2 million in 2019 to 1.0655 billion in 2024 and is projected to exceed 1.2 billion by 2030 and 1.5 billion by 2035. Over the same period, the number of patients with SHPT has also continued to rise and is expected to reach approximately 189.9 million by 2030 and 221.7 million by 2035, highlighting a substantial and growing unmet medical need.

    “We are very pleased to collaborate with Micot. As the global burden of chronic kidney disease continues to rise, addressing patients’ unmet needs remains a top priority.,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “MT1013 represents an innovative asset with the potential to expand treatment options for patients with secondary hyperparathyroidism. Through this partnership, we aim to leverage our expertise in autoimmune-related kidney disorders while broadening our renal portfolio to include additional diseases, including glomerulonephritis and complications associated with dialysis. Looking ahead, we will jointly advance the development and commercialization of MT1013 to bring innovative treatment options to a broader population of patients with kidney disease.”

    “We are delighted to enter into this strategic collaboration with Everest Medicines. Everest’s deep expertise in nephrology and established commercialization capabilities make it an ideal partner to bring MT1013 to patients in China and beyond,” said Dr. Bing Wang, Founder, Chairman, and President of Micot. “MT1013 is a pivotal achievement of our peptide technology platform and a key milestone in our commitment to advancing innovative therapies for chronic diseases. Its unique dual-targeting mechanism has the potential to deliver meaningful advances in the treatment of secondary hyperparathyroidism. We look forward to working closely with Everest to accelerate clinical development and commercialization, address critical unmet medical needs, and advance care for patients with kidney disease.”

    MT1013 has completed its pivotal Phase II clinical trial, which demonstrated robust and sustained iPTH suppression in patients with SHPT undergoing maintenance hemodialysis. In head-to-head comparisons with etelcalcetide, MT1013 showed advantages in comprehensive disease management, achieving higher rates of simultaneous control of iPTH, serum calcium, and phosphate, as well as greater reductions in phosphate and the cardiovascular risk marker FGF-23. Over 52 weeks of treatment, MT1013 also resulted in significant improvements in bone mineral density and bone metabolism markers, supporting the potential clinical benefits of its unique dual-target mechanism in both disease management and bone health.

    Building on these positive results, the Phase II data were presented orally and in a Late-Breaking session at the 2025 American Society of Nephrology Annual Meeting. MT1013 has now advanced into a confirmatory Phase III clinical trial in China with cinacalcet as the active comparator. The Phase III study has been launched across more than 100 sites nationwide, aiming to enroll approximately 424 patients, specifically targeting individuals with SHPT undergoing maintenance hemodialysis due to chronic kidney disease.

    About MT1013
    MT1013 is the world’s first-in-class dual-targeting receptor agonist polypeptide that simultaneously targets the Calcium-Sensing Receptor (CaSR) and the Osteogenic Growth Peptide (OGP) receptor and is primarily developed with Secondary Hyperparathyroidism as its leading indication and is planned to expand into additional indications including Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) with Osteoporosis and SHPT not on Dialysis. MT1013 completed its Phase II clinical trial (MT1013-II-C01) for the treatment of SHPT in May 2025 and has entered a Phase III clinical trial using Cinacalcet as the active comparator.

    About Everest Medicines
    Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies.

    The Company’s therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company’s website: www.everestmedicines.com.

    About Micot
    Shaanxi Micot Pharmaceutical TechnologyCo., Ltd.(“Micot”) was founded in Xi’an in January 2007 and now operates in China (Xi’an, Suzhou, Beijing, Shanghai, Hong Kong) and the U.S. An R&D-driven innovator, Micot develops dual- and multi-functional peptide drugs for cardiovascular/cerebrovascular and metabolic diseases to address unmet clinical needs.

    As the proposer, implementer, validator, and developer of the bispecific peptide concept, Micot stands as a premier platform for peptide drug R&D. It utilizes a unique mechanism for screening multi-target peptide therapeutics and possesses platform-based R&D capabilities to develop both First-in-class and Best-in-class candidates.

    Currently, Micot has a robust reserve of new drug candidates, with seven proprietary innovative pipelines currently in clinical stage: one in Phase III, three in Phase II, and three in Phase I. Dedicated to creating breakthrough medicines and saving lives, Micot strives to address unmet clinical needs and leverages scientific innovation to safeguard human health. For more information, please visit the website: www.micot.cn.

    Forward-Looking Statements
    This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

  • AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States

    Industry recognition for the third consecutive year reinforces AGFA HealthCare’s clinician-first commitment, and leadership in empowering connected, high-performance imaging environments

    AGFA HealthCare today announced that it has been named Best in KLAS® 2026 across three Enterprise Imaging segments in the United States, with two awards earned for the second consecutive year, underscoring the company’s continued leadership in delivering clinician-first imaging solutions trusted by healthcare organizations worldwide.

    The recognition comes as KLAS Research marks its 30th anniversary, celebrating three decades of amplifying the voice of healthcare providers through independent, data-driven insights.

    AGFA HealthCare’s Best in KLAS distinctions reflect strong customer validation of its Enterprise Imaging platform – designed to empower clinicians to stay in their flow, reduce complexity across imaging workflows, and enable confident clinical decision-making through connected, high-performing access to images and data.

    Best in KLAS® – Enterprise Imaging (United States)

    • Enterprise Imaging for Radiology: ranked #1 with a 93.2% score in the PACS (Small – under 300k studies) segment.
    • XERO® Viewer: ranked #1 with a 92.1% score in the Universal Viewer (Imaging) segment for the third consecutive year
    • Enterprise Imaging VNA: ranked #1 with a 89.8% score in the Vendor Neutral Archive (VNA) segment for the second consecutive year.

    “Being recognized across three Enterprise Imaging segments – including multiple consecutive wins – is a powerful affirmation of our clinician-first strategy,” said Nathalie McCaughley, President of AGFA HealthCare. “Healthcare organizations trust us to deliver imaging environments that truly support clinicians in their daily work, while enabling IT and clinical leaders to operate with confidence, performance, and long-term vision. This recognition reflects the strength of our partnerships and our unwavering focus on empowering care teams through connected, intelligent imaging.”

    Commenting on the awards, Adam Gale, CEO of KLAS Research, said:

    “The Best in KLAS winners have earned the trust of their customers over the past year. With this recognition, they set the standard for excellence through partnership in healthcare technology and services in the months to come.”

    Monique Rasband, Global Vice President of Imaging at KLAS Research, added:
    “AGFA HealthCare’s strong performance across multiple Enterprise Imaging segments reflects consistent customer feedback. Organizations recognize the value of solutions that help imaging teams work efficiently today while providing a clear path for future growth and innovation.”

    The Best in KLAS awards are based on direct feedback from healthcare providers and recognize vendors who consistently demonstrate excellence through partnership, performance, and responsiveness to customer needs.

    AGFA HealthCare will celebrate its Best in KLAS recognition during HIMSS 2026, alongside customers and partners, as part of its continued commitment to advancing connected, intelligent, and human-centered imaging at scale.

    KLAS references

    About AGFA HealthCare
    At AGFA HealthCare, we understand that striking the critical balance between clinical efficiency and quality patient care starts with the clinician experience. We recognize how vital it is for clinicians to be fully immersed in their cases, channeling all their energy into delivering confident, informed diagnoses. That’s why we designed our Enterprise Imaging platform to eliminate the barriers that get in the way. When distractions melt away, technology feels like an extension of one’s thought process, and each clinician has everything they need to perform at the top of their craft. That’s life in flow.

    This belief shapes everything we do – guided by our Mission, Vision, and Customer Delivery Principles, which are designed to empower clinicians and elevate their experience.

    AGFA HealthCare is a division of the Agfa-Gevaert Group. For more information on AGFA HealthCare, please visit www.agfahealthcare.comand follow us on LinkedIn.

    AGFA and the Agfa rhombus are registered trademarks of Agfa-Gevaert N.V. Belgium or its affiliates. XERO is a registered trademark of Agfa HealthCare N.V. Belgium or its affiliates. All information contained herein is intended for guidance purposes only, and the characteristics of the products and services described in this publication can be changed at any time without notice. Products and services may not be available for your local area. Please contact your local sales representative for availability information. AGFA HealthCare diligently strives to provide as accurate information as possible but shall not be responsible for any typographical error.

    About KLAS Research
    KLAS Research is a leading healthcare IT data and insights company dedicated to improving global healthcare delivery by amplifying the voice of healthcare providers. Celebrating its 30th anniversary in 2026, KLAS evaluates vendor performance through independent research based on direct customer feedback.

    Best in KLAS® is a registered trademark of KLAS Research.

    Press Contact: Jessica Baldry, Global Marketing & Communications Manager, AGFA HealthCare +44 1206 413052 jessica.baldry@agfa.com

    SOURCE: Agfa HealthCare